DavidPerlmutterMD · 2026-03-31 · David Perlmutter (host), Will Van Derveer
The Radical Idea Changing Mental Health Treatment | Will Van Derveer, MD
28 claims checked against research: 3 contradicted 2 overstated 4 needing context 15 supported 4 unverified
4 No source found (not proven false)
An ayahuasca experience typically lasts around 6 to 8 hours, whereas an ibogaine experience usually lasts around 72 hours.
"The difference between an ayahuasca ceremony in South America and that ibogaine ceremony, the ayahuasca experience tends to be about 6 hours, maybe 8 hours. The ibogaine experience, it's usually more like 72 hours." (said at 0:00:00)
No published record matching the claimed comparative durations of action for ayahuasca (~6–8 hours) and ibogaine (~72 hours) was located in PubMed; this does not prove the claim false.
A specialized 40 hertz light and sound stimulation device (EVY light by Optoceutics) achieved a 94% adherence rate and improvements across mood, energy, focus, sleep, and memory.
"So there is a company called Optoceutics, they've solved this problem with a patented technology that still gives you the 40 hertz light flashing, but through light that looks and feels quite normal. It's the device I actually have on my desk when I'm working and that's why this company sees a 94% adherence rate and significant improvements across various metrics including mood, energy, focus, sleep and memory." (said at 0:26:00)
No published record matching the claim that Optoceutics' EVY light device achieved a 94% adherence rate and significant improvements across mood, energy, focus, sleep, and memory was located; this does not prove the claim false. Published literature on Optoceutics' invisible spectral flicker technology consists of acute electrophysiological studies in healthy volunteers evaluating comfort and 40 Hz steady-state visually evoked potentials, as well as published trial protocols (such as the ALZLIGHT and FELIX studies), but peer-reviewed clinical trial results demonstrating a 94% adherence rate or multidomain clinical improvements have not been published.
Studies are being conducted on psychedelic treatments for alcohol and tobacco use disorders at UAB in Birmingham, Alabama.
"So, we are seeing um some really beautiful studies uh being done with alcohol use disorder, um tobacco uh use disorder as well uh down at uh UAB in Birmingham, Alabama." (said at 0:42:10)
No published record matching the claim that studies on psychedelic treatments for alcohol use disorder and tobacco use disorder were conducted at the University of Alabama at Birmingham (UAB) was located; this does not prove the claim false. Published clinical trial research on psilocybin for substance use disorder at UAB evaluated cocaine use disorder (PMID 42096204), whereas landmark psilocybin trials for tobacco smoking cessation were conducted at Johns Hopkins University (PMID 41805956).
The search did find related studies, but none that directly tests this claim:
Forecasts predict that 20% to 25% of American adults will be taking a GLP-1 agonist in five years.
"The prediction is that in 5 years probably 20 to 25% of all Americans, adults are going to be on a GLP-1, which say what you will." (said at 0:45:17)
No published scientific study or epidemiological forecasting model was located that predicts 20% to 25% of American adults will be taking GLP-1 receptor agonists in five years. While observational data show rapid growth in GLP-1 prescription volume (e.g., reaching 1.5 million monthly obesity medication prescriptions by early 2024), specific long-term prevalence projections of 20–25% for the entire adult population appear in financial analyst reports or media commentary rather than peer-reviewed medical literature. This does not prove the claim false, but no peer-reviewed record matching this specific forecast was found.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.